November 17, 2016 / 12:56 PM / 3 years ago

BRIEF-AzurRx BioPharma, Mayoly-Spindler initiate phase II clinical trial of MS1819-SD

Nov 17 (Reuters) - AzurRx BioPharma Inc

* Azurrx biopharma-mayoly spindler grants co marketing rights for recombinant lipase in various geographies, including exclusive rights for north america

* Azurrx biopharma inc - initial study results from ms1819-sd phase ii study are expected in first half of 2017

* Azurrx biopharma inc - azurrx and laboratoires mayoly spindler are party to a joint research and development agreement

* Azurrx biopharma and mayoly-spindler announce initiation of phase ii clinical trial of ms1819-sd for exocrine pancreatic insufficiency in chronic pancreatitis patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below